Overview

A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis

Status:
Withdrawn
Trial end date:
2026-02-13
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess efficacy and safety of pirtobrutinib in participants with relapsing multiple sclerosis.
Phase:
Phase 2
Details
Lead Sponsor:
Loxo Oncology, Inc.
Collaborator:
Eli Lilly and Company
Treatments:
Pirtobrutinib